Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.64 |
| ▸ | RXRB | P28702 | 5/20 | 0.64 |
| ▸ | RXRG | P48443 | 3/20 | 0.64 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.60 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.60 |
| ▸ | HNF4A | P41235 | 3/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6915899 | 0.81 | RXRA (0.76) | RXRARXRBRXRGHNF4ANR4A1 | |
| SCHEMBL16926940 | 0.79 | RXRA (1.00) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL6915796 | 0.78 | RXRA (0.65) | RXRARXRBRXRGHNF4ANR4A1 | |
| SCHEMBL30218800 | 0.76 | RXRA (1.00) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL2807932 | 0.76 | RXRA (1.00) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL6913487 | 0.75 | RXRA (0.65) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL6917253 | 0.75 | RXRA (0.65) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL8898043 | 0.75 | RXRA (0.65) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| Ammonia Solution, Strong SCHEMBL8706695 | 0.75 | RXRA (0.97) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| Ammonia Solution, Strong SCHEMBL8706692 | 0.75 | RXRA (0.97) | RXRARXRBRXRGCYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | claimed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | claimed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | claimed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.